Glucagon vs GLP-1

Glucagon and GLP-1 come from the same gene (proglucagon) yet have opposite effects on blood glucose. Glucagon releases glucose from the liver; GLP-1 enhances insulin secretion when glucose is high.

HPLC tested · JanoshikJanoshik CertificatesNationwide DeliveryResearch Only

🧪

Glucagon

The pancreatic alpha-cell hormone that raises blood glucose — the counter-regulatory partner to insulin and a component of newer multi-agonist research molecules.

BEST STUDIED FOR

Incretin & metabolic

Read the cited profile →

🧪

	Glucagon	GLP-1
The key difference	Raises blood glucose	Lowers blood glucose (glucose-dependent)
Class	Incretin & metabolic	Incretin & metabolic
Mechanism	Glucagon binds the glucagon receptor (GCGR), mainly on liver cells, driving glycogen breakdown and glucose production.	GLP-1 is cut from proglucagon in gut L-cells and some brainstem neurons.
Status	An approved medicine for severe hypoglycaemia, available as injectable, nasal and ready-to-use aqueous analogue (dasiglucagon) forms; glucagon-receptor antagonists have also been explored.	Endogenous hormone and research reference; long-acting analogues (semaglutide, liraglutide, dulaglutide, tirzepatide) are approved medicines.
Reported safety signals	Trials report safety and tolerability for rescue formulations comparable to reconstituted glucagon injection; glucagon-receptor blockade has brought its own adverse effects in research.	Native GLP-1 is too short-lived for therapeutic use; class effects of its analogues are gastrointestinal first.
A key study	In a phase 3 randomised trial in adults with type 1 diabetes, median time to glucose recovery was 10 minutes with dasiglucagon versus 40 minutes with placebo. (Diabetes Care 2021, PMID 35239971)	A foundational review of GLP-1 production from proglucagon and its physiological actions. (Physiol Rev 2007, PMID 17928588)

The pair illustrates why multi-agonists that include a glucagon arm still need GLP-1 activity to protect glucose control. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.

REFERENCES (PUBMED)

[Glucagon] Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial — Diabetes Care 2021. PMID 35239971
[Glucagon] Intranasal versus injectable glucagon for hypoglycemia in type 1 diabetes: systematic review and meta-analysis — Acta Diabetol 2020. PMID 32025860
[Glucagon] Low-Dose Glucagon to Prevent and Treat Exercise-Associated Hypoglycemia in Individuals With Type 1 Diabetes: A Systematic Review and Meta-analysis — Diabetes Care 2025. PMID 40834249
[GLP-1] The physiology of glucagon-like peptide 1 — Physiol Rev 2007. PMID 17928588
[GLP-1] Glucagon-like peptide 1 (GLP-1) — Mol Metab 2019. PMID 31767182
[GLP-1] Glucagon-like peptide-1 (GLP-1) signalling in the brain: From neural circuits and metabolism to therapeutics — Br J Pharmacol 2022. PMID 34519026

FREQUENTLY ASKED

What is the difference between Glucagon and GLP-1?

Glucagon and GLP-1 come from the same gene (proglucagon) yet have opposite effects on blood glucose. Glucagon releases glucose from the liver; GLP-1 enhances insulin secretion when glucose is high.

What is the regulatory status of Glucagon and GLP-1?

Glucagon: An approved medicine for severe hypoglycaemia, available as injectable, nasal and ready-to-use aqueous analogue (dasiglucagon) forms; glucagon-receptor antagonists have also been explored. GLP-1: Endogenous hormone and research reference; long-acting analogues (semaglutide, liraglutide, dulaglutide, tirzepatide) are approved medicines.

What safety signals have been reported?

Glucagon: Trials report safety and tolerability for rescue formulations comparable to reconstituted glucagon injection; glucagon-receptor blockade has brought its own adverse effects in research. GLP-1: Native GLP-1 is too short-lived for therapeutic use; class effects of its analogues are gastrointestinal first.

Which studies is this comparison based on?

For Glucagon: “Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial” (PMID 35239971); “Intranasal versus injectable glucagon for hypoglycemia in type 1 diabetes: systematic review and meta-analysis” (PMID 32025860); “Low-Dose Glucagon to Prevent and Treat Exercise-Associated Hypoglycemia in Individuals With Type 1 Diabetes: A Systematic Review and Meta-analysis” (PMID 40834249). For GLP-1: “The physiology of glucagon-like peptide 1” (PMID 17928588); “Glucagon-like peptide 1 (GLP-1)” (PMID 31767182); “Glucagon-like peptide-1 (GLP-1) signalling in the brain: From neural circuits and metabolism to therapeutics” (PMID 34519026).